$39.57
−2.56%Oct 15, 2026, 23:59 UTC
Sanofi kicked off a collaboration with RECURSION PHARMACEUTICALS, INC. to develop drug molecules.
Source:Oct 15, 2026, 23:59 UTC
RECURSION PHARMACEUTICALS, INC. shares rose 11.23%.
Source:Oct 15, 2026, 16:02 UTC
Sanofi and the pan-Canadian Pharmaceutical Alliance signed a letter of intent to support patient access to Dupixent through Canadian public drug plans for four indications in dermatology and respiratory care.
Source:Oct 15, 2026, 12:51 UTC
Recursion Pharmaceuticals reported that Sanofi exercised an option on a development candidate under their research collaboration, triggering a $10 million milestone payment.
Source:Oct 14, 2026, 08:26 UTC
The European Commission accepted Sanofi’s concessions to settle an antitrust probe into its marketing messages about a rival flu shot.
Source:Oct 6, 2026, 12:03 UTC
Regeneron Pharmaceuticals agreed to dismiss its lawsuit against Sanofi over access to material information on Dupixent commercialization and audit rights under the Antibody License and Collaboration Agreement.
Oct 5, 2026, 17:59 UTC
Judge Zahid N. Quraishi of the U.S. District Court for the District of New Jersey held the initial case management conference in the federal multidistrict litigation alleging that Dupixent (dupilumab) can cause, accelerate or unmask cutaneous T-cell lymphoma (CTCL).
Source:Oct 3, 2026, 14:45 UTC
A Russian air strike on Friday, Oct. 2 set fire to a pharmaceutical storage warehouse belonging to Ukrainian drug distributor Venta near Kyiv, destroying inventories of medicines made by Bayer, Sanofi, Pfizer, Teva, Darnytsia and Farmak.
Source:Sep 28, 2026, 22:00 UTC
The U.S. CDC reinstated its earlier, broader COVID-19 vaccine recommendations, including for children and younger adults, in compliance with a March 2026 court stay, even though some uses are off-label relative to FDA approvals.
Source:Sep 28, 2026, 16:00 UTC
Morningstar moved Sanofi, LPL Financial Holdings, Edison International, SBA Communications, and Stellantis to 5-star ratings from 4 stars after their share prices fell over the past week.
Source:Sep 25, 2026, 21:34 UTC
Health Canada announced that Sanofi-Aventis Canada is recalling insulin pens and insulin cartridges that may have been frozen during transport.
Sep 25, 2026, 07:00 UTC
The Swiss Re Foundation, with partners Digital Connected Care Coalition, AXA EssentiALL, Sanofi Global Health Unit Impact Fund, and Philips Foundation, opened applications for the 10th edition of its Entrepreneurs for Resilience 2027 programme, offering US$1.3 million in funding and support to social enterprises delivering affordable primary healthcare in low- and middle-income countries.
Source:Sep 22, 2026, 23:59 UTC
Florida Attorney General James Uthmeier announced a lawsuit in Tampa against insulin manufacturers Eli Lilly, Novo Nordisk and Sanofi, pharmacy benefit managers CVS Caremark, Express Scripts and Optum Rx, and rebate aggregators Zinc, Ascent and Emisar, alleging price-fixing, anti-competitive behavior and deceptive trade practices in insulin and diabetes-related drugs.
Sep 22, 2026, 01:10 UTC
On September 21, Yifan Pharmaceutical and South Korea's Boryung Pharmaceutical announced a partnership under which Yifan Pharmaceutical obtained exclusive general agency rights for Taxotere (docetaxel injection) in China, handling promotion, distribution and commercialization there.
Sep 17, 2026, 07:15 UTC
Bavarian Nordic A/S appointed Tarja Stenvall as President and Chief Executive Officer effective October 15, 2026, succeeding Paul Chaplin.
Sep 16, 2026, 14:31 UTC
Sanofi announced a C$925 million investment in Canada, including C$415 million in partnership funding from the Canadian government and C$55 million from the Ontario provincial government.
Source:Sep 16, 2026, 14:30 UTC
Sanofi's C$925 million influenza vaccine manufacturing facility in Toronto began production.
Sep 16, 2026, 08:52 UTC
Sanofi inaugurated its Shanghai foreign-invested R&D innovation center, which will become its largest translational medicine research center in China, and signed an excellence translational center cooperation agreement with Huashan Hospital affiliated with Fudan University.
Source:Sep 14, 2026, 14:57 UTC
Specialty pharmaceutical company CHEPLAPHARM announced the acquisition of Sanofi.
Source:Sep 14, 2026, 13:07 UTC
Sanofi agreed to acquire a 26.4% stake in Cheplapharm and to sell 20 medicines and three production sites to Cheplapharm.
Sep 9, 2026, 00:20 UTC
On the fifth and final day of the 2026 national medical insurance drug list negotiations, price consultations for the commercial insurance innovative drug catalog began, with multiple pharmaceutical companies including AstraZeneca, Sanofi, and subsidiaries of Kechi Life and Hengrundasheng entering the venue.
Sep 7, 2026, 16:30 UTC
Pharmaceutical company Sanofi announced an investment of nearly $300 million in a Toronto AI Center of Excellence.
Source:Aug 17, 2026, 19:23 UTC
Sanofi will lay off 229 workers in Massachusetts, affecting employees of Blueprint Medicines, which Sanofi acquired in a $9.1 billion deal in July 2025.
Source:Aug 9, 2026, 23:16 UTC
Sanofi alerted patient groups and physicians in the U.S. and Europe that supplies of Myozyme and Nexviazyme are dwindling due to a bottleneck in the final manufacturing phase and quality control issues at its Waterford plant.
Source:Jul 21, 2026, 16:00 UTC
Sanofi announced an evolution of its Executive Committee to support its next strategic chapter.
Source:Jul 13, 2026, 20:01 UTC
Paulo Fontoura resigned from the Board of Directors of Lakefront Biotherapeutics NV after being appointed Global Head of R&D at Sanofi SA.
Page 1Next →